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SUMMARY
RING and U-box E3 ubiquitin ligases regulate diverse
eukaryotic processes and have been implicated in
numerous diseases, but targeting these enzymes
remains a major challenge. We report the develop-
ment of three ubiquitin variants (UbVs), each binding
selectively to the RING or U-box domain of a distinct
E3 ligase: monomeric UBE4B, phosphorylated active
CBL, or dimeric XIAP. Structural and biochemical
analyses revealed that UbVs specifically inhibited
the activity of UBE4B or phosphorylated CBL by
blocking the E2Ub binding site. Surprisingly, the
UbV selective for dimeric XIAP formed a dimer to
stimulate E3 activity by stabilizing the closed
E2Ub conformation. We further verified the inhibi-
tory and stimulatory functions of UbVs in cells. Our
work provides a general strategy to inhibit or activate
RING/U-box E3 ligases and provides a resource for
the research community tomodulate these enzymes.
INTRODUCTION
Ubiquitination is a post-translational modification that is required
for virtually all cellular processes (Hershko and Ciechanover,
1998). Ubiquitination involves the covalent attachment of the
small protein ubiquitin (Ub) to N termini or lysines of proteins
by the E1-E2-E3 enzyme cascade, and different Ub chains
confer distinct functions on protein substrates (Komander and
Rape, 2012; Pickart and Eddins, 2004). Ub ligases (E3s) mediate
the final step of the process and control specificity, efficiency,
and patterns of ubiquitination. Consequently, dysregulation of
E3s occurs inmany diseases, including diabetes, neurodegener-
ation, atherosclerosis, and cancer (Goru et al., 2016; Popovic
et al., 2014), and E3s are attractive therapeutic targets (Nalepa
et al., 2006; Petroski, 2008).
E3s are classified into three families: RING (really interesting
new gene) and U-box E3s, HECT (homologous to E6AP C
terminus) E3s, and RBR (RING between RING) E3s (Buetow
and Huang, 2016). With 600 members, the RING/U-box E3s
form the largest family (Deshaies and Joazeiro, 2009). This family
uses a RING or U-box domain to recruit E2 enzymes thioesteri-
fied with Ub (E2Ub) and facilitates transfer of Ub directly to
substrate. RING/U-box E3s can be further categorized as multi-
subunit complexes, which contain scaffold, adaptor, receptor,
and RING subunits on distinct polypeptide chains (Deshaies
and Joazeiro, 2009), or simple, which contain E2Ub and
substrate-binding domains within the same polypeptide chain.
Some simple RING/U-box E3s are active as monomers, like
CBL and UBE4B, whereas others, like XIAP (X-linked inhibitor
of apoptosis), only function when dimerized via their E2Ub
binding domains (Buetow and Huang, 2016).
Despite the plethora of RING/U-box family members,
small molecule modulators are limited to a few E3-substrate
interactions (Bulatov and Ciulli, 2015; Landre´ et al., 2014).
Substrate-binding domains vary among E3s; hence, new
screening strategies are required to establish a general targeting
platform. Although a RING or U-box domain is a common
feature, these domains lack binding pockets easily targeted by
inhibitors. Thus, we sought to develop a general platform to
systematically modulate activities of RING and U-box E3s.
RING/U-box domains promote Ub transfer by shifting the
equilibrium of E2Ub into a closed conformation (Dou et al.,
2012b; Plechanovova´ et al., 2012; Pruneda et al., 2012). These
domains comprise 75–100 aa that form two loops stabilized
by two Zn2+ ions or hydrogen bonds in RING or U-box domains,
respectively. These loops and intervening region form
the E2Ub-binding surface in RING-E2Ub complexes, and
the C-terminal tail and Ile36 patch of Ub form interactions
with the RING while the Ile44 hydrophobic patch abuts the
E2 (Buetow and Huang, 2016). Typically, a small surface area
of only 450 A˚2 from the RING domain contacts Ub.
Previously, we used phage display to select for ubiquitin
variants (UbVs) with enhanced affinities for proteins that
naturally interact weakly with Ub (Ernst et al., 2013), including
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deubiquitinases, HECT E3s, multi-subunit E3s, and small
Ub-interacting motifs (Brown et al., 2016; Ernst et al., 2013; Gor-
elik et al., 2016; Manczyk et al., 2017; Zhang et al., 2016, 2017a,
2017b). Here, we tested whether UbV modulators can be
selected for simple RING E3s. We targeted three RING/U-box
E3s from three important classes: (1) UBE4B, a monomeric U-
box E3 (Wu et al., 2011); (2) CBL, a monomeric RING E3 acti-
vated by phosphorylation (Dou et al., 2012a); and (3) XIAP, a
RING E3 that is activated upon dimerization (Nakatani et al.,
2013). We generated selective UbVs for each RING/U-box
domain and used biochemical assays and structural studies to
identify two types of UbVs: competitive inhibitors of E2Ub
binding sites on UBE4B or phosphorylated CBL and an activator
of XIAP. Our work demonstrates the versatility of the UbV tech-
nology and provides a resource for the rapid development of in-
hibitors and activators across the large RING/U-box E3 family.
RESULTS
Identification of Selective UbVs for RING and U-box E3s
Using phage-displayed UbV library 2 (Zhang et al., 2016;
Figure 1A) and a well-established strategy (Figure 1B), we
conducted binding selections with the U-box from UBE4B
(E4B, residues 1079–C) and the RING domains from Tyr371-
phosphorylated c-CBL (pCBLR, residues 354–435) and XIAP
(XR, residues 434–C). Aiming to isolate the highest-affinity
variants, we increased stringency by reducing the target protein
amount and increasing the washes in each selection round. After
five rounds, phage ELISAs with 96 individual clones yielded 6,
90, and 77 positive clones for E4B, pCBLR, and XR, respectively.
Consistent with the high stringency selection, DNA sequencing
revealed a single unique UbV in each case (Figure 1A). Further
phage ELISAs revealed that wild-type Ub did not bind or bound
very weakly to nine RING/U-box E3s, whereas each selected
UbV, named UbV.E4B, UbV.pCBL, and UbV.XR, bound with
much higher affinity exclusively to E4B, pCBLR, and XR, respec-
tively (Figure 1C). The specificities were validated by performing
ELISAs with purified UbVs and Ub (Figure 1D).
To investigate the effects of the UbVs on ligase activity, we
performed autoubiquitination assays with GST-tagged E4B,
pCBLR, and XR. The E2 UbcH5B was charged with Ub before
adding a mixture of each GST-tagged E3 domain with its
cognate UbV or Ub lacking the C-terminal diglycine (Ub74) as
a negative control. UbV.E4B and UbV.pCBL inhibited their
cognate E3s, whereas, unexpectedly, UbV.XR stimulated
autoubiquitination of GST-XR (Figure 1E). We next undertook
further biochemical and structural studies of the three E3-UbV
pairs to elucidate the molecular basis for selectivity and activity.
UbV.E4B Inhibits UBE4B via the E2Ub Binding Site
UbV.E4B selectively inhibited E4B, the U-box domain of UBE4B
(Figure 1). To elucidate the inhibitory mechanism, we measured
the affinity of UbV.E4B for E4B and tested its activity in single-
turnover lysine discharge assays with UbcH5B containing an
S22R substitution (UbcH5B S22R). This activity assay was
chosen to eliminate potential effects on acceptor Ub interactions
in the enzyme-substrate complex and to prevent stimulation ofUb
transfer from E2Ub by non-covalent binding of Ub to UbcH5B’s
backside (Brzovic et al., 2006; Buetow et al., 2015). UbV.E4B
bound to E4B with an affinity of 1.9 mM by surface plasmon
resonance (SPR) (Table 1; Figure S1), but it only weakly inhibited
E4B-mediated lysine discharge (Figure 2A), even at 500 mM.
UBE4B is known as a Ub elongation factor or E4 because it
binds preformed Ub conjugates and catalyzes formation of
polyubiquitin chains (Kaneko et al., 2003; Koegl et al., 1999). In
cells, UBE4B only facilitates Ub chain elongation on p53 after
initial ubiquitination by MDM2 (Wu et al., 2011). We speculated
that UbV.E4B may have stronger effects on polyubiquitin chain
formation and thus performed single-turnover Ub transfer
autoubiquitination assays with GST-E4B. Indeed, formation of
ubiquitinated GST-E4B was inhibited in a concentration-depen-
dent manner by UbV.E4B at 100 or 500 mM, but there were no
obvious effects on product formation by 20 mM UbV.E4B,
despite being at approximately ten times the KD (Figure 2B).
We next examined whether UbV.E4B functions in cells.
Co-immunoprecipitation assays on lysates from HEK293T cells,
in which hemagglutinin (HA)-taggedUbV.E4B (HA-UbV.E4B) and
Myc-tagged UBE4B (Myc-UBE4B) were overexpressed,
confirmed an interaction between UBE4B and UbV.E4B (Fig-
ure 2C). Moreover, HA-UbV.E4B, but not HA-Ub74, decreased
ubiquitination of GFP-tagged p53 (Figure 2D). These data
show that UbV.E4B binds UBE4B and inhibits its activity in cells.
We attempted to co-crystallize UbV.E4B with several E4B
U-box variants of differing lengths. A crystal structure of
UBE4B U-box comprising residue 1,097 to the C terminus
(E4B1097–C) was determined to a resolution of 1.48 A˚ (Table 2;
Figure S2A), but no crystals of a complex with UbV.E4B were
obtained. We therefore undertook nuclear magnetic resonance
(NMR) experiments to map the complex interface. Since
UBE4B primarily functions as an E4 ligase, E4B might
Figure 1. Identification of Selective UbVs for RING and U-box Domains
(A) Sequence alignment of Ub and UbVs selective for the RING domain of pCBL or XIAP or the U-box domain of UBE4B. The alignment only shows regions that
were diversified in the UbV library. Dashes indicate positions in which the Ub sequence is conserved.
(B) The four-step procedures to conduct phage display selections for UbV binders of RING/U-box E3 ligases. Please refer to the STARMethods for details of the
selection cycle.
(C) The binding specificities of phage-displayed UbVs (y axis) are shown across a group of RING domains from nine E3s (x axis), as assessed by phage ELISA.
Sub-saturating concentrations of UbV phage were added to immobilized proteins as indicated. Bound phage were detected by the addition of anti-M13-HRP and
colorimetric development of TMB peroxidase substrate. The mean value of absorbance at 450 nm is shaded in a white-purple gradient.
(D) ELISAs for UbVs or Ub binding to RING/U-box E3s. GST-tagged RING/U-box domains from nine E3s (1 mM, 30 mL) were incubated with indicated amounts of
FLAG-tagged UbV or Ub (0–62.5 nM, 30 mL). Bound UbV was detected by anti-FLAG-HRP conjugate antibody and colorimetric development of TMB peroxidase
substrate. Absorbance at 450 nm (y axis) was plotted against UbV concentration (x axis). Data are presented as the mean ± SD (n = 3).
(E) Reduced autoradiograms showing the formation of 32P-Ub products over time with GST-E4B (top), GST-pCBLR (center), or GST-XR (bottom) in the presence
of Ub74 (left) or their respective UbVs (right).
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preferentially interact with mono-Ub or polyUb chains. To rule
this out, we titrated 15N-Ub with E4B or K48-diUb with
15N-E4B. In each case, negligible chemical shift perturbations
(CSPs) were observed, suggesting that E4B does not directly
interact with mono- or polyUb (Figures S2B and S2C).
With UbV.E4B in place of Ub, a dramatically different picture
emerged. With 15N-UbV.E4B, numerous large CSPs were
observed across a number of peaks, including in one of the
two tryptophan indole groups (Figure S3A), whereas in the
titration of UbV.E4B into 15N-E4B, the CSPs were more localized
(Figure S3B). Residue-specific CSPs for 15N-E4B were gener-
ated from these data (Figure 2E), and residues with CSPs > 1s
were mapped onto the structure of UBE4B in complex with
UbcH5C (PDB: 3L1Z; Figure 2F). Next, we used SPR to investi-
gate effects of substitutions at selected positions (L1107R,
T1122R, F1141R, and R1143A) on UbV.E4B binding. Binding
was either abrogated or reduced by 10- to 20-fold (Table 1; Fig-
ure S1). Notably, these CSPs on E4B mapped to the same
residues involved in E2 and E2Ub binding based on the crystal
structure of the UBE4B-UbcH5C complex (Benirschke et al.,
2010) (Figure 2F) and NMR chemical shift analysis of the
UBE4B-UbcH5CUb complex (Pruneda et al., 2012), respec-
tively. To investigate whether UbV.E4B and E2 compete for the
same binding site on E4B, we monitored CSPs in 15N-UbcH5B
competition experiments. Addition of equimolar E4B to
15N-UbcH5B strongly affected several residue peaks within the
spectra indicating formation of 15N-UbcH5B-E4B complex.
Subsequent titration of UbV.E4B caused 15N-UbcH5B signals
to shift back to free E2 positions (Figure 2G; Figure S3C), showing
that UbV.E4B inhibits E4B by occupying the E2-binding site.
InhibitionbyUbV.pCBLReliesonTyr371-Phosphorylation
of CBL
The three human isoforms of CBL (c-CBL or CBL, CBL-B, and
CBL-C) share homology between their N-terminal regions
comprising a substrate tyrosine kinase binding domain (TKBD),
linker, and RING domain (Swaminathan and Tsygankov, 2006).
In cells, tyrosine kinase substrate ubiquitination by CBL requires
phosphorylation of the conserved Tyr371, which resides on the a
helix within the linker (Dou et al., 2012a; Levkowitz et al., 1999).
To investigate the selectivity of UbV.pCBL, we measured its
affinity for several CBL variants by SPR and tested its activity
against these variants in single-turnover lysine discharge assays
with UbcH5B S22R.
In native CBL, Tyr371 is buried in a pocket on the TKBD and
stabilizes the RING domain in a catalytically incompetent confor-
mation (Dou et al., 2012a; Zheng et al., 2000). Tyr371 phosphor-
ylation abolishes the TKBD-linker interaction and frees the RING
domain to adopt conformations in which the TKBD substrate-
binding site is accessible. In addition, phosphorylated Tyr371
(pTyr371) locks into the RING domain and interacts with E2Ub
to prime it for catalysis (Dou et al., 2012a, 2013). Both unphos-
phorylated c-CBL RING (CBLR) and pCBLR were included in
our panel of E3s, but only pCBLR bound to UbV.pCBL (Figure 1).
Correspondingly, UbV.pCBL bound pCBLR tightly in SPR
(KD = 120 nM) but did not bind detectably to CBLR (Table 1; Fig-
ure S1). In activity assays, UbV.pCBL inhibited discharge of
UbcH5B S22RUb by pCBLR, but not CBLR (Figure 3A).
Because the RING-TKBD domain interactions change upon
phosphorylation of Tyr371 (Dou et al., 2012a), we investigated
whether this impacts RING-UbV interactions by conducting
assays with a longer pCBL variant encompassing the TKBD,
linker, and RING domains (pCBL47–435). pCBL47–435 and pCBLR
had similar affinities for UbV.pCBL in SPR (KD = 250 and
120 nM, respectively, Table 1; Figure S1), and formation of
ubiquitinated-pCBL47–435 and discharge of UbcH5B S22RUb
in single-turnover Ub transfer assays were slowed by UbV.pCBL
(Figure 3B). Together, these data show that UbV.pCBL binds
pCBLR, but not CBLR, and inhibits RING-mediated Ub transfer.
We determined the crystal structure of UbV.pCBL in complex
with pCBL47–435 and the ZAP70-TKBD-substrate peptide to
Table 1. DissociationConstants or Interactions betweenRINGE3
Variants, UbVs, and UbcH5B S22R C85K-Ub
Immobilized
Protein Analytea KD (mM)
Binding
enhancement
(Fold)b
E4B UbV.E4B 1.9 ± 0.5 –
E4B1097–C UbV.E4B 9 ± 1 –
E4B L1107R UbV.E4B No binding –
E4B T1122R UbV.E4B 19 ± 3 –
E4B F1141R UbV.E4B 25 ± 8 –
E4B R1143A UbV.E4B 16 ± 2 –
pCBLR UbV.pCBL 0.12 ± 0.02 –
CBLR UbV.pCBL No binding –
pCBL47-435 UbV.pCBL 0.25 ± 0.04 –
pCBLRM374R UbV.pCBL 1.6 ± 0.2 –
pCBLR I383R UbV.pCBL Poor or no
binding
–
pCBL-B UbV.pCBL 1.3 ± 0.1 –
pCBL-C UbV.pCBL 1.1 ± 0.2 –
XR UbV.XRM 1.1 ± 0.2 –
XR UbV.XRD 0.11 ± 0.02 –
XR UbV.XR A10G No binding –
XR UbV.XR K48F 2.4 ± 0.2 –
XR UbV.XR K48R 0.21 ± 0.04 –
XR UbcH5B S22R
C85K–Ub
12.2 ± 0.3 –
XR UbcH5B S22R
C85K-Ub + 10 mM
UbV.XR
5.5 ± 0.7 2.2
XR UbcH5B S22R
C85K-Ub + 10 mM
UbV.XR K48F
15.1 ± 0.4 0.8
XR UbcH5B S22R
C85K-Ub + 10 mM
UbV.XR K48R
4.0 ± 0.2 3.0
SEM and dissociation constants (KD) are indicated. Number of replicates,
representative sensorgrams, and binding curves are shown in Figure S1.
aAnalytes containing fixed concentration of UbV.XR variants are
indicated.
bThe degree of binding enhancement of UbcH5B S22R C85K-Ub in the
presence of UbV.XR is determined by dividing the KD in the absence by
the KD in the presence of indicated UbV.XR variants.
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2.47 A˚ (Figure 3C; Table 2). In the complex, pCBL47–435 is in the
active conformation in which pTyr371 supports the E2Ub bind-
ing site and the RING domain is in a catalytically competent
conformation oriented toward the bound ZAP70 substrate
peptide on the TKBD (Dou et al., 2012a, 2013). UbV.pCBL
interacts with the E2Ub binding site on the RING domain and
Figure 2. Mechanism of E4B Inhibition by UbV.E4B
(A) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over timewith lysine only or
indicated concentrations of UbV.E4B or Ub74 in the presence (left) or absence (right) of E4B.
(B) Non-reduced autoradiograms of single-turnover GST-E4B mediated Ub transfer reactions showing the disappearance of UbcH5B S22R32P-Ub and
appearance of 32P-Ubn-GST-E4B and other
32P-Ubn-products over time with indicated concentrations of UbV.E4B or Ub74 in the presence (left) or absence
(right) of GST-E4B.
(C) Co-immunoprecipitation assay of lysates from HEK293T cells transfected with plasmids expressing Myc-tagged UBE4B and HA-tagged UbV.E4B.
Immunoprecipitates with anti-Myc antibody and cell lysates were analyzed by immunoblotting with anti-Myc, anti-HA, or anti-Actin antibodies as indicated.
(D) Immunoblots of p53 ubiquitination in HEK293T cells transfected with plasmids expressing GFP-tagged p53 and HA-tagged UbV.pCBL or Ub74. The cell
lysates and GFP immunoprecipitates were analyzed by immunoblotting with anti-Ub, anti-GFP, anti-HA, or anti-Actin antibodies as indicated.
(E) Changes in CSP (DCSP) determined by 1H-15N HSQC NMR for each residue of 15N-E4B following addition of 1.77-fold molar excess of UbV.E4B. Changes
were calculated according to the equation [(dHA – dHB)
2 + ((dNA – dNB)/5)
2]1/2. The dashed line represents a DCSP value of 1s (0.014 ppm), where s corresponds to
standard deviation. See also Figure S3B.
(F)Mapping of changes in CSPs from (E) (>1s) onto theU-box domain of UBE4B in the structure of UBE4B (green) bound toUbcH5C (cyan) (PDB: 3L1Z). Residues
that undergo perturbations are labeled and shown as sticks. The active site Cys85 on UbcH5C is also shown as sticks and labeled. N, O, and S atoms are colored
blue, red, and magenta, respectively.
(G) CSP data of representative residue peaks from UbcH5B in competition with UbV.E4B for binding to E4B. 1H-15N HSQC spectra for free 15N-UbcH5B (black),
bound to E4B (green), and subsequently titrated with UbV.E4B where [UbV.E4B]:[15N-UbcH5B] is 1:1 (magenta), 5:1 (orange), and 10:1 (red).
Table 2. Data Collection and Refinement Statistics
XR-UbV.XR UbV.XR ZAP70 peptide-pCBL47–435-UbV.pCBL E4B1097–C
Data Collection
PDB PDB: 5O6T PDB: 5O6S PDB: 5O76 PDB: 5O75
Space group P212121 I2 P212121 P622
Cell dimensions
a, b, c (A˚) 35.7, 70.0, 109.8 48.2, 71.7, 118.0 94.8, 101.3, 117.3 80.2, 80.2, 39.5
a, b, g () 90, 90, 90 90, 94.7, 90 90, 90, 90 90, 90, 120
Resolution (A˚) 43–1.57 (1.61–1.57)a 61–2.90 (3.07–2.90) 35–2.47 (2.54–2.47) 40–1.48 (1.51–1.48)
Rmerge (%) 6.6 (80.3) 16.9 (52.3) 11.2 (115.0) 4.3 (119.4)
Rpim (%) 4.2 (51.3) 16.7 (51.3) 6.6 (66.7) 1.5 (43.5)
Completeness (%) 100 (96.3) 99.4 (99.3) 93.3 (99.0) 91.9 (100.0)
Multiplicity 6.4 (5.0) 2.9 (2.9) 6.5 (6.9) 17.0 (15.2)
I/sI 14.9 (2.0) 3.7 (1.5) 13.9 (2.1) 27.9 (2.2)
CC(1/2) 0.999 (0.663) 0.966 (0.725) 0.998 (0.796) 1.000 (0.771)
Wilson B (A˚2) 20.57 58.40 59.34 25.70
Refinement
Rwork (%) 15.8 26.3 21.8 19.5
Rfree (%) 18.6 30.9 24.8 22.4
No. atoms
Protein 4961 3582 9266 549
Water 218 32 235 44
Ligand / ion 4 0 6 0
RMSD bond 0.01 0.008 0.008 0.008
RMSD angle 1.15 1.06 0.95 1.03
B factors
Main chain 23.41 52.71 66.07 37.86
Side chain 30.92 64.57 72.96 43.63
Zn2+ 16.80 – 51.00 –
Water 40.87 20.37 54.88 48.15
aValues in parentheses are for highest resolution shell.
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inhibits Ub transfer by blocking E2Ub binding (Figure 3C). Our
pCBL47–435 structure and a previous model (PDB: 4A4B) super-
pose with a root-mean-square-deviation (RMSD) of 1.37 A˚ for
379 Ca atoms, whereas the TKBD and linker/RING domains
can be superposed with the corresponding regions with RMSD
values of 1.21 and 0.64 A˚ for 303 Ca and 74 Ca atoms, respec-
tively (Figures S4A–S4E).
The main difference between the two structures of pCBL47–435
is a shift of the RING domain in relation to the TKBD caused by
binding of UbV.pCBL (Figures S4A–S4E). UbV.pCBL resembles
Ub, as the two superpose with an RMSD of 0.76 A˚, but substitu-
tions in region 3 (Figure 1) of the UbV mediate interactions with
pTyr371; Tyr66 and Tyr68, replacing Thr66 and His68 in Ub,
form a hydrophobic cap around Met374 at the C terminus of
the linker helix and Tyr68 interacts with the phosphate moiety
of pTyr371 (Figure 3D). UbV.pCBL also stacks against the sec-
ond Zn2+-binding site on the RING domain via a hydrophobic
patch formed by substitutions in positions 8–12 (Figure 3E). To
validate these interactions, we measured binding of UbV.pCBL
to pCBLR variants containing an M374R or an I383R substitu-
tion, which are expected to perturb UbV interactions with the
linker or the second Zn2+-binding site, respectively. Binding
was reduced in both cases, with a KD of 1.6 mM for the M374R
substituted variant and no detectable binding for the I383R
substituted variant (Table 1; Figure S1). To investigate the roles
of substitutions within regions 1 and 3 in conferring selectivity
of UbV.pCBL, we reverted key positions in pairs to wild-type
sequence (G8L/P11K and Y66T/Y68H). Both reversion variants
failed to inhibit pCBLR-mediated discharge of UbcH5B
S22RUb (Figure 3F).
Next, we investigated the selectivity of UbV.pCBL for the RING
domains from different CBL isoforms. CBLR shares 95% and
60% sequence identity with the RING domains of CBL-B and
CBL-C, respectively. In SPR assays, UbV.pCBL bound pCBL-B
and pCBL-C with KDs of 1.3 and 1.1 mM, respectively (Table 1;
Figure S1) and inhibited discharge of UbcH5B S22RUb by
both E3 isoforms (Figure 3G). These data show that UbV.pCBL
binds selectively and inhibits the activity of the three phosphor-
ylated isoforms but does not recognize CBL in its unphosphory-
lated state.
In unstimulated cells, CBL is predominantly unphosphorylated
and inactive. Stimulation with EGF induces phosphorylation of
Tyr371, which activates CBL-mediated ubiquitination of EGFR
(Dou et al., 2012a; Levkowitz et al., 1999). To determine whether
UbV.pCBL can selectively bind pCBL in cells, we performed
co-immunoprecipitation assays in HEK293T cells with over-
expressed HA-tagged UbV.pCBL (HA-UbV.pCBL) and
Myc-tagged CBL (Myc-CBL) with and without EGF stimulation.
Immunoprecipitation of HA-UbV.pCBL only co-precipitated
Myc-CBL following EGF stimulation, demonstrating that
UbV.pCBL only binds CBL following an event that increases
the population of pCBL (Figure 3H). Moreover, ubiquitination of
EGFR only occurred following EGF stimulation but was
decreased when UbV.pCBL was present, showing that
UbV.pCBL inhibits ubiquitination of EGFR by pCBL (Figure 3I).
Endosomal trafficking and lysosomal degradation of EGFR are
highly dependent on its ubiquitination (Tomas et al., 2014), so we
examined whether UbV.pCBL could alter the fate of activated
EGFR. UbV.pCBL decreased EGFR accumulation in early endo-
somes as evidenced by reduced co-localization of EGFR with
the early endosomal marker EEA1 upon EGF stimulation (Fig-
ure 3J; Figure S4F). Activated EGFR was also more stable in
the presence of UbV.pCBL, which resulted in prolonged
downstream signaling events as shown by extended ERK1/2
Figure 3. Mechanism of pCBL Inhibition by UbV.pCBL
(A) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over time with pCBLR
(top row), CBLR (middle row), or no E3 (bottom row) in the presence of lysine only (left), Ub74 (middle), or UbV.pCBL (right).
(B) Non-reduced autoradiograms of single-turnover Ub transfer reactions mediated by pCBL47–435 showing the disappearance of UbcH5B S22R32P-Ub and
appearance of 32P-Ubn-pCBL47–435 and other
32P-Ubn products over time in the presence of 10 mM Ub74 (left) or UbV.pCBL (right).
(C) Cartoon representation of the UbV.pCBL-pCBL47–435 -ZAP70 substrate peptide complex. ZAP70 substrate peptide is colored brown, UbV.pCBL is colored
orange, and the TKBD, linker, and RING domains of pCBL47–435 are colored blue-gray, yellow, and green, respectively. Zn
2+ and Ca2+ ions are depicted as gray
and light cyan spheres, respectively. The side chain of pTyr371 is shown as sticks with oxygen and phosphorous atoms colored red and pink, respectively.
(D) Close-up view of the interface between UbV.pCBL and the region around pTyr371 of pCBL47–435. Key interacting residues are shown as sticks. Coloring is as
described in (C) and Figure 2. S and N atoms are colored magenta and blue, respectively. The dashed black line depicts a putative hydrogen bond.
(E) Close-up view of the interface between UbV.pCBL and the second Zn2+-binding loop in pCBL47–435. Coloring is as described in (D).
(F) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over time with pCBLR and
UbV.pCBL variants as indicated.
(G) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over time with pCBLR
(top row), pCBL-B (middle row), or pCBL-C (bottom row) and Ub74 (left) and UbV.pCBL (right).
(H) Co-immunoprecipitation assay of lysates from HEK293T cells transfected with plasmids expressing Myc-tagged CBL and HA-tagged UbV.pCBL with and
without EGF stimulation. Immunoprecipitates with anti-HA antibody and cell lysates were analyzed by immunoblotting with anti-Myc, anti-HA, or anti-Actin
antibodies as indicated.
(I) Immunoblots of EGFR ubiquitination with and without EGF stimulation from lysates of HEK293T cells transfected with plasmids expressing His-tagged Ub,
FLAG-tagged EGFR, and HA-tagged UbV.pCBL or Ub74 and treated with MG132. The cell lysates and Ni-NTA pull-down products were analyzed by
immunoblotting with anti-FLAG, anti-HA, or anti-Actin antibodies as indicated.
(J) Merged images from HeLa cells overexpressing UbV.pCBL or Ub74 and treated with EGF as indicated. Cells were incubated with anti-EGFR and anti-EEA1
primary antibodies, followed by secondary antibodies conjugated to AF488 (EGFR, green) or AF594 (EEA1, red). DAPI was used to stain the nuclei. Scale bars in
each panel represent 100 mm.
(K) Immunoblots of cell lysates from HEK293T cells overexpressing HA-tagged UbV.pCBL or Ub74 and treated with EGF for indicated time. Lysates were
analyzed by immunoblotting with anti-EGFR, anti-pERK1/2 (T202/Y204), anti-ERK1/2, anti-pAKT (S473), anti-AKT, anti-HA, and anti-Actin antibodies.
(L) Bar graphs showing transcript levels of EGFR-regulated genes fromH1299 cells overexpressing UbV.pCBL or Ub74with or without EGF treatment. Quantitative
RT-PCR was performed to check the levels of CCND1, MYC, iNOS, VEGF, and EGR1. The bars represent 95% confidence intervals for relative expression.
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and AKT phosphorylation (Figure 3K). Activated EGFR is a
transcriptional co-activator of several oncogenes, such as the
Cyclin D1 gene CCND1, MYC, iNOS, VEGF, and EGR1 (Brand
et al., 2011). We found that the transcript levels of these
EGFR-regulated genes were increased in cells overexpressing
UbV.pCBL after EGF stimulation (Figure 3L). Together, these
data show that UbV.pCBL selectively binds and inhibits pCBL
in cells, thereby perturbing the signaling and transcriptional
activities of its substrate EGFR.
Dimeric UbV.XR Stimulates XIAP
UbV.XR binds selectively to the RING domain of XIAP (residues
434–C, referred to as XR), but not the RING domain of BIRC2
(residues 555–C, referred to as B2R), and stimulates autoubiqui-
tination of XR (Figure 1). To validate these findings, we performed
single-turnover lysine discharge assays using UbV.XRwith XR or
B2R. A multi-step purification of UbV.XR resulted in the isolation
of two distinct fractions by gel filtration chromatography (Fig-
ure 4A). The earlier and later fractions eluted at volumes
consistent with a dimer (UbV.XRD) and a monomer (UbV.XRM),
respectively. At 10 mM, both fractions stimulated XR-mediated
UbcH5B S22RUb discharge to a similar extent, whereas
Ub74 did not (Figure 4B). Titration of the two UbV fractions
revealed that UbV.XRD stimulated XR slightly better at lower
concentrations (Figures 4C and 4D). Correspondingly, UbV.XRD
bound XR with 10-fold higher affinity compared to UbV.XRM in
SPR assays (Table 1; Figure S1).
Due to its higher activity, we used UbV.XRD for further studies.
UbV.XRD stimulated discharge of UbcH5B S22RUb by XR, but
not by B2R (Figure 4E), and no interaction between B2R and
UbV.XRD was detected by SPR (Table 1; Figure S1). Further-
more, SPR did not detect any interaction between UbV.XRD
and the RING domain of BIRC3 or BIRC7 despite high sequence
and structural homology between these proteins and XIAP
(Table 1; Figure S1). Investigation of the stimulatory capabilities
of UbV.XRD in the context of autoubiquitination of full-length
XIAP and ubiquitination of the XIAP substrate mature SMAC
(mSMAC, residues 56–C) in single-turnover Ub transfer assays
revealed that UbV.XRD promoted Ub transfer in both assays
(Figure 4F).
To examine UbV.XR activity in cells, we monitored ubiquitina-
tion of mSMAC by endogenous XIAP in HEK293T cells in which
UbV.XR was overexpressed. We confirmed that the UbV and its
cognate E3 interact in cells by performing pull-down experi-
ments on lysates in which HA-tagged UbV.XR (HA-UbV.XR)
and Myc-tagged XIAP (Myc-XIAP) were overexpressed (Fig-
ure 4G). Cells were exposed to etoposide to initiate mitochon-
drial outer membrane permeabilization and the release of
mSMAC from the mitochondria. Upon induction of apoptosis,
an increase of ubiquitinated mSMAC was detected in cells over-
expressing UbV.XR (Figure 4H). These results show that UbV.XR
is selective for XIAP and enhances its ligase activity in cells.
We determined the crystal structure of XR bound to UbV.XRD
to 1.57 A˚ (Figure 5A; Table 2) but were unable to obtain crystals
of an XR-UbV.XRM complex. XR adopts a dimeric RING domain
arrangement similar to structures of BIRC3 and BIRC7 in which
the C-terminal tail of each subunit interacts with the second
subunit (Dou et al., 2012b; Mace et al., 2008). UbV.XRD forms a
symmetrical domain-swapped dimer in which b1 is flipped 180
away from the b sheet of its own subunit and is replaced by b10
from the other subunit. Whereas residues 6–9 in wild-type Ub
form the loop between b1 and b2, in the UbV dimer they extend
b1 and participate in hydrogen bonding with b20 and b10 to
form a continuous anti-parallel b sheet across the two subunits
(Figure 5A). We also determined the crystal structure of UbV.XRD
alone to 2.9 A˚ resolution and observed a dimer conformation
similar to that of the dimer in the complex with XR, but the relative
orientations of the two subunits differed by 30 (RMSD of 0.46 A˚
for 66 Ca atoms of a single subunit of UbV.XRD and RMSD of
3.3 A˚ for 133 Ca atoms of both subunits of UbV.XRD, Figures
S5A–S5C; Table 2), suggesting conformational flexibility between
the two UbV.XR subunits when not in complex. Apart from the
domain swap, the overall fold of a single subunit of UbV.XRD is
similar to that of wild-type Ub, with an RMSD of 0.4 A˚ for 72 Ca
atoms, if b10 is treated as b1 (Figure S5D).
In the complex, the UbV dimer forms a groove that cradles the
RING dimer (Figure 5A), covering a surface area of 816 A˚2 that is
remote from the E2Ubbinding site. The groove is formed by the
b2-b10-b1-b20 b sheet that comprises the UbV dimer interface.
Two symmetrical hydrophobic pockets at the base of the groove
bind the two Phe490 residues from the XR dimer (Figure 5B).
Residues from both subunits of UbV.XRD comprise each hydro-
phobic pocket and include substitutions relative to wild-type Ub
(Figures 1 and 5B). Symmetrical salt bridges between UbV.XRD
Glu46 side chains (Ala46 in Ub) and XR Lys472 side chains
also appear to stabilize the complex.
To validate these interactions, we tested the binding and activ-
ity of variants that contained substitutions in residues from the
complex interface: T489E or F490R substitution in XR and I8R
or L68R substitution in UbV.XR (Figure 5B). Both XR variants
had elution volumes comparable to wild-type XR (data not
shown) and UbV.XR L68R had an elution volume comparable
to UbV.XRD, whereas UbV.XR I8R had an elution volume compa-
rable to UbV.XRM (Figure 5C). UbV.XRD did not stimulate
UbcH5B S22RUb discharge catalyzed by XR T489E or XR
F490R, even though both variants were comparably active to
wild-type XR in promoting UbcH5B S22RUb discharge in the
presence of Ub74 (Figure 4E). Similarly, neither UbV.XR I8R
nor UbV.XR L68R stimulated UbcH5B S22RUb discharge
catalyzed by XR (Figure 5D).
Modeling suggests that if the UbV.XR monomer adopts a fold
similar to wild-type Ub, it cannot form the continuous b sheet
comprising the XR-binding groove. Yet, UbV.XRM still retains
the ability to bind XR and stimulate UbcH5B S22RUb
discharge (Figure 4B; Figures S1, S5E, and S5F; Table 1). To bet-
ter understand this phenomenon, we used gel filtration chroma-
tography to monitor the stability of UbV.XR monomer and dimer
over time and found that the monomer was slowly converted to
dimer whereas the dimer was stable (there was no evidence of
dissociation to monomer or formation of larger oligomers (Fig-
ure 4A). We sought to substitute a residue that would abrogate
formation of the UbV dimer but would not affect interactions
with XR, but all residues that form the UbV dimer interface also
interact with XR. We postulated that reverting Ala10 to Gly as
found in Ub might fulfill our criteria because only the main chain
of Ala10 is involved in interactions with XR, whereas the side
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Figure 4. UbV.XR Stimulates the E3 Ligase Activity of XIAP In Vitro and In Cells
(A) Scaled Superdex75 chromatograms of UbV.XR during purification (black) showing the protein eluting at volumes consistent with dimer (UbV.XRD) and
monomer (UbV.XRM), of UbV.XRD after 7 days at 4
C (cyan), and of UbV.XRM after 7 days at 4C (red).
(B) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over time in the absence
(left) or presence (right) of XR with lysine only (top row), Ub74 (second row), UbV.XRM (third row), or UbV.XRD (fourth row).
(C) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over time with XR in the
presence of indicated concentrations of UbV.XRM or UbV.XRD. Concentrations were determined from A280 measurements using the calculated molar extinction
coefficient and predicted mass of a monomer.
(D) Quantification of single-turnover lysine discharge as shown in (C) at 1.5 min with 1.11 mMUbV.XRM or UbV.XRD. Data are presented as an average ± 1s (n = 4).
(E) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over time with XR variants
or B2R in the presence of Ub74 (left) or UbV.XRD (right).
(F) Non-reduced autoradiograms of XIAPmediated single-turnover Ub transfer reactions showing the disappearance of UbcH5B S22R32P-Ub and appearance
of 32P-Ubn-XIAP (top) or
32P-Ubn-mSMAC (bottom) over time in the presence of Ub74 (left) or UbV.XRD (right).
(G) Co-immunoprecipitation assay of lysates from HEK293T cells transfected with plasmids expressing Myc-tagged XIAP and HA-tagged UbV.XR.
Immunoprecipitates with anti-Myc antibody and cell lysates were analyzed by immunoblotting with anti-Myc, anti-HA, or anti-Actin antibodies as indicated.
(H) Immunoblots of HEK293T cell lysates to detect ubiquitination of mSMAC by XIAP in the presence of UbV.XR or Ub74, with or without etoposide and treated
with MG132. Ni-NTA pull-down products/cell lysates were analyzed by immunoblotting with anti-SMAC, anti-HA, and anti-Actin antibodies as indicated.
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Figure 5. Proposed Mechanism for the Activation of XIAP by UbV.XR
(A) Cartoon representation of XR in complex with UbV.XRD. The subunits of the XR dimer are colored green and yellow and those of UbV.XRD are colored orange
and white. Zn2+ ions are depicted as gray spheres.
(B) Close-up view of the UbV.XRD-XR dimer interface. Key residues are shown as sticks and coloring is as in (A) and Figure 3.
(C) Overlaid gel filtration Superdex 75 chromatograms of UbV.XR I8R (purple), UbV.XR L68R (black), UbV.XR A10G (blue), UbV.XR K48F (green), and UbV.XR
K48R (red).
(legend continued on next page)
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chain is buried in a pocket on the secondUbV subunit (Figure 5E).
Gel filtration chromatography revealed that UbV.XR A10G was
exclusively a monomer during purification and remained a
monomer after incubation at 4C for 1 week (Figure 5C; data
not shown). The UbV.XR A10G variant showed no evidence of
binding to XR in SPR assays (Table 1; Figure S1) and did not
stimulate XR-mediated UbcH5B S22RUb discharge (Fig-
ure 5D). Taken together, these findings suggest that UbV.XR
dimerization is critical for XR binding and stimulation.
To elucidate how UbV.XR stimulates Ub transfer by XR, we
generated a model of the XR-UbV.XRD complex bound to
UbcH5BUb based on the structure of the BIRC7-UbcH5B-Ub
complex (Dou et al., 2012b) (Figure 5F). The model suggests
that UbV.XRD contacts the C terminus of a1 from donor Ub
independently of its interactions with XR. We postulated that
these interactions might help position donor Ub for transfer.
To test this hypothesis, we generated stably conjugated
UbcH5B S22R C85K-Ub to mimic UbcH5BUb as described
(Dou et al., 2013), and SPR analyses of XR binding to this stable
conjugate showed that UbV.XRD enhanced affinity by 2-fold
(Table 1; Figure S1).
An electrostatic surface potential map of our model suggests
that interactions between UbV.XR and donor Ub may involve an
acidic patch surrounding Asp32 on Ub and a basic patch
encompassing the region between Lys48 and Arg54 on UbV.XR
(Figures S6A–S6C). One of these electrostatic interactions is a
putative hydrogen bond between Lys48 of UbV.XRD and Gln31
of Ub (Figure 5G). We postulated that these electrostatic
interactions might help prime donor Ub for transfer, so we
substituted Gln31 on Ub with Arg and examined whether
UbV.XRD could promote XR-mediated discharge of UbcH5B
S22RUbQ31R. In the presence of Ub74, discharge of UbcH5B
S22RUb and UbcH5B S22RUb Q31R by XR were compara-
ble whereas with UbV.XRD, discharge of the former E2Ub was
stimulated, but not the latter (Figure 5H). Next, we substituted
Lys48 of UbV.XRD with Phe or Arg and tested the ability of these
variant dimers to stimulate XR in discharge assays.We predicted
that a Phe48 substitution would disrupt the electrostatic interac-
tions whereas an Arg48 substitution would not. UbV.XRK48F did
not stimulate XR-mediated discharge of UbcH5B S22RUb
whereas UbV.XR K48R did (Figure 5D). SPR analyses of XR
binding to UbcH5B S22R C85K-Ub in the presence of each of
these UbVs showed that, like UbV.XRD, UbV.XR K48R enhanced
binding by 3-fold whereas UbV.XR K48F did not (Table 1; Fig-
ure S1). These results support our hypothesis that when bound
to XR, UbV.XRD interacts directly with donor Ub to help stabilize
it in a primed conformation, thereby stimulating XR-mediated
Ub transfer.
DISCUSSION
There is a paucity of technologies to selectively modulate
components of the ubiquitination pathway at the protein level
in cells. RING and U-box E3s pose a particular challenge for
probe development because they often have multiple sub-
strate-binding domains, as in the case of XIAP, or they have
functions beyond Ub ligation, as in the case of CBL. Moreover,
someRING andU-box domains exhibit very high sequence iden-
tity, thus making probe selectivity problematic. Here, we used a
phage-displayed library to identify UbVs that selectively bound
and modulated the activity of UBE4B, pCBL or XIAP. UbV.E4B
and UbV.pCBL occupy the E2Ub binding sites of their respec-
tive U-box and RING domains and inhibit Ub transfer, whereas
UbV.XR forms a dimer that occupies a site on the RING dimer
in which it stabilizes donor Ub and stimulates Ub transfer.
Our UbV library was originally designed to develop inhibitors of
deubiquitinases (Ernst et al., 2013). Recently, we showed that
UbVs could exhibit multiple binding modes and mechanisms to
modulate HECT E3 activity (Zhang et al., 2016)—one set occu-
pied the HECT domain E2-binding site and inhibited Ub ligation.
Here, our structural studies show that the E2Ub-binding site of
RING/U-box is also targetable by UbVs. Therefore, a generaliz-
able strategy is now available to potentially generate potent
and specific inhibitors for over 300 humanRING/U-box domains.
Our study of HECT E3s also identified UbVs that bind to a
Ub-binding exosite and stimulate ubiquitination activity (Zhang
et al., 2016). In contrast to HECT domains, in which a large sur-
face area of19,000 A˚2 is available for binding, RING and U-box
domains only present a total surface area of 5,000 A˚2 or
7,600 A˚2 as monomers or dimers, respectively. Given this
relatively small surface area, it is noteworthy that UbV.XR acti-
vates E3 activity through binding to a region on XIAP that has
not previously been reported to be involved in protein-protein
interactions. These data demonstrate the versatility of our UbV
technology for exploiting both canonical and non-canonical
protein-protein interaction surfaces of RING and U-box domains
to develop selective probes.
All three UbVs were active in vitro and in cells, thereby
providing valuable tools for probing the cellular functions of
UBE4B, CBL, and XIAP. In addition to regulating p53 stability
and function (Wu et al., 2011), ubiquitination by UBE4B also
plays a role in endosomal sorting and lysosomal degradation
of EGFR and probably regulates sorting of other membrane pro-
teins (Sirisaengtaksin et al., 2014). UbV.E4B will be useful for
discovering additional pathways subject to UBE4B-mediated
ubiquitination. CBL functions as both an adaptor and a negative
regulator in tyrosine kinase-mediated signaling. It attenuates
(D) Non-reduced autoradiograms of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22R32P-Ub over time with XR in the
presence of Ub74 or UbV.XR variants as indicated.
(E) Close-up view of UbV.XRD Ala10. Residues within 5 A˚ are shown as sticks and coloring is as in (A) and Figure 3.
(F) Model of UbV.XR-XR complex bound to UbcH5B-Ub. The model was generated by superposing the RING domains from BIRC7 RING-UbcH5B-Ub complex
(PDB: 4AUQ) and UbV.XR-XRwithout any adjustment to residue positions. Coloring is as described in (A); UbcH5B is colored cyan and donor Ubwheat. An arrow
points to the UbcH5B-Ub linkage (in red).
(G) Close-up of interactions between UbV.XR and donor Ub. Coloring is as described in (E) and (F).
(H) SDS-PAGE of single-turnover lysine discharge reactions showing the disappearance of UbcH5B S22RUb (top) or UbcH5B S22RUb Q31R (bottom) over
time with XR in the presence of lysine only (left), Ub74 (middle), or UbV.XRD (right).
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signaling by ubiquitinating receptor and non-receptor tyrosine
kinases and targeting them for degradation. Substrate ubiquiti-
nation involves the N-terminal region of CBL encompassing
the TKBD, linker, and RING domain and requires phosphoryla-
tion of Tyr371, whereas the adaptor functions of CBL are medi-
ated by a proline-rich region and the C terminus (Levkowitz et al.,
1999; Swaminathan and Tsygankov, 2006). UbV.pCBL only
binds CBL when it is phosphorylated on Tyr371, thus providing
a tool to differentiate between its ligase and adaptor functions
in cells. XIAP inhibits apoptosis by binding Caspase-3, -7,
and -9, and it activates NFkB signaling by binding the upstream
adaptor TAB1.Moreover, it is upregulated in several cancers and
confers resistance to chemotherapy-induced cell death (Obexer
and Ausserlechner, 2014). Small molecule inhibitors, such
as SMAC mimetics, have been developed to target the
baculovirus-IAP-repeat (BIR) domain, but these molecules also
target the BIR domains of the inhibitor of apoptosis family E3s
(Bai et al., 2014). The E3 ligase activity of the RING domain of
XIAP controls its stability and ubiquitinates substrates such as
Caspase-3 and mSMAC (MacFarlane et al., 2002; Suzuki et al.,
2001). The specificity of UbV.XR for XIAP and its role as a stim-
ulator of E3 activity will enable further studies of hyperactive
XIAP in cells and will enhance understanding of how E3 activity
could influence its function.
Our data suggest that UbV.XR stimulates XIAP-mediated Ub
transfer by binding the RING domain and stabilizing donor Ub
in a conformation primed for catalysis. Only one other RING E3
has a similar mechanism: free Ub binds the RING domain of
the monomeric E3 Arkadia and is postulated to directly contact
and position donor Ub for transfer (Wright et al., 2016). However,
UbV.XR and free Ub bind to different regions of the XIAP and
Arkadia RING domains, respectively, and consequently contact
different surfaces on donor Ub. Moreover, our data indicate that
UbV.XR must dimerize to stimulate XIAP-mediated Ub transfer.
The b strand domain swap in the UbV.XR dimer appears to be
a unique arrangement for a Ub-based dimer. In solution, free Ub
has a KD of 5 mM for the monomer-dimer equilibrium, and the
two subunits in the dimer adopt a range of relative orientations
involving residues from Ub’s b sheet (Liu et al., 2012). Once
UbV.XR dimer has formed, no shift to monomer is observed (Fig-
ure 4A), but the two dimeric subunits have some degree of
flexibility relative to one another. Comparison to a range of Ub
dimers involving isopeptide linkages with the N terminus or one
of Ub’s Lys residues reveals that UbV.XR most closely resem-
bles compact diUb chains linked through Lys6, Lys11, or
Lys33 (RMSD ranging from 5.4 to 6.2 A˚) (Bremm et al., 2010;
Hospenthal et al., 2013; Matsumoto et al., 2010; Virdee et al.,
2010), but modeling XR with any of these diUb chains super-
posed onto UbV.XR reveals potential clashes. We identified
the G10A substitution in UbV.XR as being essential for UbV
dimerization, but other substitutions may also contribute.
Importantly, a phage-displayed dimeric UbV library can now be
constructed using UbV.XR as a template, and such a library
holds great potential for developing activators of other IAP
proteins and other dimeric RING/U-box E3s.
A powerful aspect of phage display technology is that li-
braries can be improved in response to new insights gained
from the results of selection experiments, functional analyses,
and structural information. Although Ub interacts with most of
its binding partners through a similar interface, there are signif-
icant differences in terms of the residues that make contacts
with different structural folds. Thus, structural analysis of the
interaction interfaces for UbVs generated thus far will allow
us to more accurately define the type of diversity that should
be included at each position within the UbV binding surface.
These insights can be used to design further optimized libraries
that are likely to yield more potent UbVs for targeting particular
structural folds.
In summary, we took advantage of the UbV technology to
identify modulators of RING and U-box E3 ligases, which can
be used in cells to explore ubiquitination pathways and signaling.
In addition to identifying competitive inhibitors that target the
E2Ub binding sites of RING and U-box E3s, we identified a
distinct surface on XIAP RING dimer that stimulated E3 ligase
activity when bound to dimeric UbV.XR. Remarkably, UbV.pCBL
recognized a specific active conformation of CBL induced
by phosphorylation of Tyr371. We conclude that the UbV
technology provides a unified platform for the rapid development
of both inhibitors and activators of the large RING/U-box E3
family.
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pRSFDuet TEV GGS-UbV.XR L68R This paper N/A
pRSFDuet TEV GGS-UbV.XR A10G This paper N/A
pRSFDuet TEV GGS-UbV.XR K48F This paper N/A
pRSFDuet TEV GGS-UbV.XR K48R This paper N/A
pRK5 HA-Ub74 This paper N/A
pRK5 HA-UbV.pCBL This paper N/A
pRK5 HA-UbV.XR This paper N/A
pcDNA3.1 Myc/His-CBL This paper N/A
pcDNA3.1 Myc/His-XIAP This paper N/A
pcDNA3.1 FLAG-EGFR This paper N/A
pcDNA3.1 His-Ub Gift from A. Hock Dou et al., 2012a
pEGFP p53 Addgene Cat#12091
Oligonucleotides
18S rRNA F 50-GCTTAATTTGACTCAACACGGGC-30 N/A
18S rRNA R 50- AGCTATCAATCTGTCAATCCTGTC-30 N/A
CCND1 F 50-CCGTCCATGCGGAAGATC-30 N/A
CCND1 R 50- GAAGACCTCCTCCTCGCACT-30 N/A
MYC F 50-CCAACAGGAACTATGACCTCGACTAC-30 N/A
MYC R 50-CTCGAATTTCTTCCAGATATCCT-30 N/A
VEGF F 50- AAATGCTTTCTCCGCTCTGA 30 N/A
VEGF R 50- CCCACTGAGGAGTCCAACAT 30 N/A
iNOS F 50-CAGCGGGATGACTTTCCAA-30 N/A
iNOS R 50-AGGCAAGATTTGGACCTGCA-30 N/A
EGR1 F 50-TTCGGATCCTTTCCTCACTC-30 N/A
EGR1 R 50- GTTGCTCAGCAGCATCATCT-30 N/A
Software and Algorithms
GraphPad Prism GraphPad Software https://www.graphpad.com;
RRID: SCR_002798
ProtParam Gasteiger et al., 2005 http://web.expasy.org/protparam/;
RRID: SCR_012880
Biacore T200 BIAevaluation GE Healthcare http://www.biacore.com;
RRID: SCR_008424N/A
Scrubber2 BioLogic Software http://www.biologic.com.au/scrubber.html;
RRID: SCR_015745
xia2 pipeline Winter, 2010 http://xia2.github.io; RRID: SCR_015746
XDS Kabsch, 2010 http://xds.mpimf-heidelberg.mpg.de/;
RRID: SCR_015652
POINTLESS Evans, 2006 http://www.ccp4.ac.uk/html/pointless.html;
RRID: SCR_014218
AIMLESS Evans and Murshudov, 2013 http://www.ccp4.ac.uk/html/aimless.html;
RRID: SCR_015747
autoPROC Vonrhein et al., 2011 https://www.globalphasing.com/autoproc/;
RRID: SCR_015748
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to Lead Contact Danny T. Huang (d.huang@beatson.gla.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Recombinant Proteins
All recombinant proteins were expressed in Escherichia coli BL21(lDE3) GOLD. Cells were grown at 37C in Luria Bertani to an OD600
of 0.6–0.8 and induced with 0.2 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) at 18–20C overnight. To generate pTyr-Cbl
variants, Cbl-encoding plasmids were co-expressed with plasmid encoding MBP-tagged Mus Src (84–526) as in Dou et al. (2012a).
To generate heterodimeric RING E3s, plasmids encoding GST-tagged MDM2 or RNF2 were coexpressed with plasmids encoding
His-tagged MDM4 or BMI1, respectively. 15N-labeled UbV.E4B and E4B were obtained from M9 minimal media according to
Cai et al. (1998). Briefly, cells were grown in 4 L of Luria Bertani media until OD600 reached 0.8-1.0, the cells were pelleted, washed
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
PHASER McCoy et al., 2007 http://www.ccp4.ac.uk/html/phaser.html;
RRID: SCR_014219
PHENIX Adams et al., 2010 https://www.phenix-online.org/;
RRID: SCR_014224
BUSTER Bricogne et al., 2016 https://www.globalphasing.com/buster/;
RRID: SCR_015653
COOT Emsley et al., 2010 https://www2.mrc-lmb.cam.ac.uk/personal/
pemsley/coot/; RRID: SCR_014222
MOLPROBITY Chen et al., 2010 http://molprobity.biochem.duke.edu/;
RRID: SCR_014226
LSQMAN Kleywegt, 1996 http://xray.bmc.uu.se/usf/lsqman_man.html;
RRID: SCR_015751
PyMOL The PyMOL Molecular Graphics
System, v.1.8.4.0, Schrodinger, LLC
https://pymol.org/; RRID: SCR_000305
PISA Krissinel and Henrick, 2007 http://www.ebi.ac.uk/pdbe/pisa/;
RRID: SCR_015749
Top Spin v3.1 Bruker https://www.bruker.com/products/mr/nmr/
nmr-software/software/topspin/overview.
html; RRID: SCR_014227
UCSF Sparky N/A http://www.cgl.ucsf.edu/home/sparky;
RRID: SCR_014228
ImageQuantTL 8.1 GE Healthcare http://www.gelifesciences.com/webapp/wcs/
stores/servlet/catalog/en/GELifeSciences-us/
products/AlternativeProductStructure_16016/
29000605; RRID: SCR_014246N
Fiji Schindelin et al., 2012 https://fiji.sc; RRID: SCR_002285
CellF Olympus http://www.dis-imaging.gr/OLYMPUS/
software.html; RRID: SCR_014342
Other
96-well MaxiSorp plates Thermo Scientific 12565135
Glutathione agarose resin Web Scientific Cat#ABT 4B-GLU-100
Ni2+ agarose resin Web Scientific Cat#ABT 6BCL-QHNi-100
Source 15Q GE Healthcare Cat#17094701
Source 15S GE Healthcare Cat#17094401
SP Sepharose Fast Flow GE Healthcare Cat# 17072901
Superdex 75 GE Healthcare Cat# 28989333
HisTrap HP GE Healthcare Cat# 17-5248-02
Protein A Sepharose CL 4B GE Healthcare Cat#17-0780-01
Protein G Sepharose 4 Fast Flow GE Healthcare Cat#17-0618-01
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in 1xM9media, all pelletes were combined into 1 L of M9media and grown for 1 hr at 37C to eliminate unlabelled precursors. Accord-
ingly, the 1 L ofM9was supplmentedwith: 1 g of 15NH4Cl, 4 g of glucose, 50mg kanamycin, and essential neutrients then grown for an
additional hour at 20C. Finally, the cells were induced using a final concentration of 0.5 mM IPTG for 20 hr. 15N-labeled Ub was
prepared following the autoinducing system from Varadan et al. (2002). In brief, 10 mL of starter culture was added to 1 L of
15N-autoinducing media containing: 1.42 g Na2SO4, 6.8 g KH2PO4, 7.1 g Na2HPO4, 1 mM MgSO4, 1 g
15NH4Cl, 100 mg ampicillin,
60 mg of Iron(III) citrate, 12.5 g glycerol, 2 g glucose, 5 g and lactose. The 1L culture was grown at 37C for 20 hr and harvested.
Cell Culture and Transfection
HEK293T cells were cultured in DMEM and H1299 and HeLa cells were cultured in RPMI, all supplemented with 10% FBS, 20 mM
L-glutamine, 100 units/ml penicillin, 0.1mg/ml streptomycin and 6mg/l gentamycin reagent solution (Invitrogen, USA). The cells were
grown in monolayer at 37C in 5% CO2. The constructs were transfected into the respective cell lines using Lipofectamine-2000
(Thermo Fisher Scientific) following manufacturer’s protocol. Cells were harvested 48 hr post transfection. The plasmids were
transfected into cells seeded on 100 mm plates as follows: Myc-tagged UBE4B (5 mg) and HA-tagged UbV.E4B (5 mg) in Figure 2C;
GFP-tagged p53 (1 mg) and HA-tagged UbV.pCBL (7.5 mg) or Ub74 (7.5 mg) in Figure 2D; Myc-tagged CBL (5 mg) and HA-tagged
UbV.pCBL (5 mg) in Figure 3H; His-tagged Ub (1 mg), FLAG-tagged EGFR (2 mg) and HA-tagged UbV.pCBL (5 mg) or Ub74 (5 mg)
in Figure 3I; HA-tagged UbV.pCBL (5 mg) or Ub74 (5 mg) in Figure 3J, Myc-tagged XIAP (5 mg) and HA-tagged UbV.XR (5 mg) in
Figure 4G, UbV.XR (5 mg) or Ub74 (5 mg), His-tagged Ub (1 mg) in Figure 4H. In Figures 3J and 3L, 2.5 mg of each plasmid were
transfected into cells seeded on 35 mm plates.
METHOD DETAILS
Selection of Ubiquitin Variants
The phage-displayed ubiquitin variant (UbV) library used in this study was re-amplified from Library 2 as previously described (Ernst
et al., 2013). Protein immobilization and the following UbV selections were done according to established protocols (Tonikian et al.,
2007). Specifically, purified RING E3s were coated on 96-well MaxiSorp plates by adding 100 mL of 1 mM proteins and incubating
overnight at 4C. Afterward, five rounds of selections using the phage-displayed UbV library were performed against immobilized
proteins, as shown in Figure 1B including the following steps: (I) Within the phage pool, each phage particle displays a unique
UbV and encapsulates the encoding DNA. (II) Protein-binding phage are captured with immobilized proteins. (III) Non-binding phage
are washed away. (IV) Bound phage are amplified by infection of bacterial host (Zhang et al., 2016). After the fifth round of binding
selections, individual phage with improved binding properties obtained from round 4 and round 5 were identified by phage ELISA
(see below) and subjected to DNA sequencing of the phagemids to obtain UbV sequences.
ELISAs to Evaluate Binding and Specificity
Phage and protein ELISA against immobilized proteins under study was performed as previously described (Zhang et al., 2016).
Briefly, GST-tagged RING/U-box domains from nine E3s (1 mM) were individually immobilized in microtiter plates (30 mL). Binding
of phage was detected using anti-M13-HRP antibody and colorimetric development of TMB peroxidase substrate. For protein ELISA
to measure the half maximal binding concentration (EC50) of UbVs binding to purified RING E3s, two-fold serial dilutions of
FLAG-tagged UbV or Ub (starting at 62.5 nM, 24 points, 30 mL) were added and incubated for 20 min at room temperature. Wells
were washed and bound UbV was detected by anti-FLAG-HRP conjugate antibody and colorimetric development of TMB peroxi-
dase substrate.
Generation of Constructs
New constructs were generated using standard PCR-ligation techniques and verified by automated sequencing. GST-tagged
constructs were cloned into pGEX4T1 (GE Healthcare) modified with a TEV cleavage site (pGEX4T1 TEV), an N-terminal uncleavable
His-tag (pGEX4T1 HG) or both as indicated (pGEX4T1 HG TEV); His-tagged constructs were cloned into pRSFDuet-1 (Merck
Millipore) modified with a TEV cleavage site following the N-terminal His-tag (pRSFDuet TEV) and HisSmt3-tagged proteins were
cloned into pET-28a (Merck Millipore) modified with a Ulp-1 cleavable hexahistidine Smt3-tag (pET-HisSmt3). Ub74 in pRSFDuet
TEV and all the UbV constructs includeDNA encoding the sequenceGGS at theN terminus prior toMet1. UntaggedUb74was cloned
into pET-3a (Merck Millipore). The following mammalian constructs were generated for the study: pRK5 HA-Ub74, pRK5
HA-UbV.pCBL, pRK5 HA-UbV.XR, pcDNA3.1 Myc/His-CBL, pcDNA3.1 Myc/His-XIAP and pcDNA3.1 FLAG-EGFR.
Protein Purification
Following expression, bacterial cells were harvested by centrifugation and lysed with a microfluidizer. Cells expressing UbVs were
resuspended in 25 mM Tris-HCl, pH 7.6, 500 mM NaCl, 5% glycerol, 15 mM imidazole, 5 mM b-mercaptoethanol (BME), 2.5 mM
phenylmethylsulfonyl fluoride (PMSF); cells expressing pTyr-Cbl variants were resuspended in PBS mixed with 350 mM NaCl,
15 mM imidazole, 5 mM BME, 2.5 mM PMSF, 2 mM NaVO4; cells expressing UbcH5B or UbcH5B S22R were resuspended in
100 mM NaCl, 50 mM MES, pH 6.5, 1 mM DTT; otherwise cells were resuspended in 25 mM Tris-HCl, pH 7.6, 200 mM NaCl,
15 mM imidazole, 5 mM BME, 2.5 mM PMSF.
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To purify GST-tagged E4B and variants, RNF38 389–C, XR and variants, B2R, BIRC3 RING, BIRC7 RING, BRE1A, pCBL47–435,
pCBLR and variants, and CBLR used for UbV selection and/or SPR, clarified lysates were incubated with glutathione agarose
resin for 1-2 hr at 4C on a rotary shaker, washed in lysis buffer lacking PMSF and NaVO4 and eluted in 50 mM Tris-HCl, pH 8.0,
200 mM NaCl, 10 mM glutathione, 5 mM DTT. GST-tagged pTyr-Cbl variants were further purified by anion exchange chromatog-
raphy (Source 15Q) using a NaCl gradient in 50 mM Tris-HCl, pH 8.5. To purify GST-MDM2/His-MDM4 and GST-RNF2/His-BMI1,
clarified lysates were incubated with Ni2+ agarose resin for 1-2 hr at 4C on a rotary shaker, washed in lysis buffer lacking PMSF
and NaVO4 and eluted in 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 200 mM imidazole, 5 mM BME. The eluate was then incubated
with glutathione agarose resin for 1-2 hr at 4C on a rotary shaker, washed in lysis buffer lacking PMSF and NaVO4 and eluted in
50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 10 mM glutathione, 5 mM DTT.
To purify HisGST-tagged or HisSmt3-tagged UbVs, clarified lysates were applied to Ni2+-affinity columns, washed in lysis buffer
lacking PMSF and eluted in 25 mM Tris-HCl, pH 7.6, 500 mM NaCl, 200 mM imidazole, 5% glycerol, 5 mM BME. HisGST-tagged
UbVs were further purified using glutathione affinity chromatography with elution in 50 mM Tris-HCl, pH 8.0, 500 mMNaCl, 5% glyc-
erol, 10 mM glutathione, 5 mM DTT. Affinity tags were cleaved with TEV or Ulp-1 and removed by Ni2+-affinity chromatography and
protein was further purified using gel filtration chromatography (Superdex 75) in 25 mM Tris-HCl, pH 7.6, 500 mMNaCl, 5% glycerol,
1 mM DTT. For HisSmt3-tagged UbV.pCBL variants, anion exchange chromatography (Source 15Q) was performed instead of gel
filtration chromatography.
To purifyArabidopsisUba1 (Dou et al., 2012b), cells overexpressing the E1weremixedwith cells overexpressing GST-Ub. Clarified
lysate from this mixture was incubated for 2 hr at 4C with 5 mM MgCl2 and 5 mM ATP, and purified using glutathione affinity
chromatography with elution in 20 mM DTT. The eluate was further purified by anion exchange chromatography (Source 15Q).
For UbcH5B (Dou et al., 2012a) and UbcH5B S22R (Dou et al., 2012b), clarified lysate was diluted to 50 mM NaCl, 50 mM MES,
pH 6.5, 1 mMDTT, loaded onto an SP Sepharose Fast Flow column, washed with 50 mMMES, pH 6.5, 50 mMNaCl, 1 mMDTT, and
eluted with 50mMMES, pH 6.5, 200mMNaCl, 1 mMDTT. The eluate was subsequently diluted to 50mMMES, pH 6.5, 50mMNaCl,
1 mM DTT, loaded onto a Source 15S column, eluted with a NaCl gradient in 50 mMMES, pH 6.5 and further purified by gel filtration
chromatography (Superdex 75) in 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM DTT.
To prepare 32P-Ub (Huang et al., 2008), clarified lysate from cells expressing GST-tagged 2TK-Ub was applied to a glutathione
affinity column, cleaved with TEV, passed back over a glutathione affinity column to remove the tag, and applied to a Superdex
75 gel filtration column in 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM DTT. To generate 32P-Ub, purified 2TK-tagged Ub was
incubated with g-32-P-ATP in 15 mM Tris-HCl pH 7.6, 100 mM NaCl, 12 mM MgCl2, 1 mM DTT for 2 hr at 23
C.
To purify E4B (HisGST-tagged) or E4B1097–C (HisSmt3-tagged), clarified lysates were applied to Ni
2+-affinity columns, washed in
lysis buffer lacking PMSF and NaVO4 and eluted in 25 mM Tris-HCl, pH 7.6, 500 mM NaCl, 200 mM imidazole, 5 mM BME. Affinity
tags were cleaved with TEV or Ulp-1 and removed by Ni2+-affinity pass-back and protein was further purified using gel filtration
chromatography (Superdex 75) in 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM DTT.
To purify pCBL47–435 (Dou et al., 2012a), clarified lysate was applied to a Ni
2+-affinity column, washed in PBS mixed with 350 mM
NaCl, 10 mM imidazole, 5 mM BME, and eluted in PBS mixed with 350 mM NaCl, 250 mM imidazole, 5 mM BME. Eluate was then
applied to a glutathione Sepharose column, eluted in 50 mM Tris-HCl, pH 8.5, 200 mMNaCl, 10 mM glutathione, 5 mMDTT, cleaved
with thrombin and applied to a Ni2+-affinity column to remove the cleaved tag. Subsequently, protein was purified by anion exchange
chromatography (Source 15Q) with a NaCl gradient in 50 mM Tris-HCl, pH 8.5 and gel filtration chromatography (Superdex 75) in
25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM DTT.
pTyr-Cbl variants were purified using the above protocol, but after elution with glutathione, protein was cleaved with thrombin and
then purified by anion exchange chromatography (Source 15Q) followed by gel filtration chromatography (Superdex 75). To purify
CBLR, the above protocol was used but instead of eluting with glutathione buffer, protein was cleaved with thrombin directly
from the beads.
To purify His-tagged Ub74, Ub Q31R, and UbV.XR variants, clarified lysates were incubated with Ni2+ agarose resin for 1-2 hr at
4C on a rotary shaker. Bound protein was washed in lysis buffer lacking PMSF and cleaved with TEV.
Complex of pCBL47–435 and UbV.pCBL was obtained by expressing GST-tagged pCBL47–435 as described above and then mixing
the resuspended cells with cells overexpressing His-tagged UbV.pCBL. Complex was purified by Ni2+-affinity and then glutathione
affinity chromatography followed by cleavage with thrombin to remove the GST-tag. Protein was then loaded onto HisTrap HP
columns, cleaved with TEV and further purified by gel filtration chromatography.
For XR and its variants, and XIAP, clarified lysate was loaded onto Ni2+-affinity columns, washed in lysis buffer lacking PMSF, and
eluted in 25 mM Tris-HCl, pH 7.6, 200 mM NaCl, 200 mM imidazole, 5 mM BME. Eluted protein was loaded onto glutathione-resin,
washed in 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM BME, and eluted in 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10 mM gluta-
thione and 5 mM DTT. The eluted protein was cleaved with TEV protease while dialyzing against 25 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 5 mM BME, passed over a Ni2+-affinity column to remove the tag and applied onto a size-exclusion chromatography column
(Superdex 75) equilibrated in 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM DTT.
mSMAC containing a C-terminal Protein Kinase A recognition sequence (RRAVS) was purified by loading clarified lysates onto Ni2+
affinity columns, washing in lysis buffer lacking PMSF, and elution in 25mMTris-HCl, pH 7.6, 200mMNaCl, 200mM Imidazole, 5mM
BME. The eluted protein was then purified by gel filtration chromatography (Superdex 75) in 25 mM Tris-HCl, pH 7.6, 150 mM NaCl.
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Preparation of untagged Ub74 and Ub variants was based on Volk et al. (2005). Cells expressing untagged Ub variants were lysed
and then 70%perchloric acid was added dropwise to the clarified lysate in an ice bath until a final concentration of 0.4%. This mixture
was centrifuged and the supernatant was dialyzed in a 3.5 kDa MWCOmembrane against 50 mM ammonium acetate, pH 4.5 at 4C
for 16 hr. The contentswere loadedonto a 16/10SPFFcolumn (GELifeSciences) andelutedusing a 0%–40%gradient over 15 column
volumes of 50 mM ammonium acetate, 1 M NaCl, pH 4.5. Ub fractions were pooled, concentrated and loaded onto a 26/60 Superdex
75 gel filtration column for exchange into PBS buffer.
K48-diUb was prepared enzymatically by following Varadan et al. (2002). The 2 mL reaction containing 20mg of Ub K48R, 20 mg of
Ub74, 10 mMof GST-UBE2K, 1 mME1, 15 mMATP, 5 mM TCEP, 10 mMMgCl2 in 50 mM Tris-HCl, pH 8.0 buffer was allowed to react
at 30C for 20 hr. K48-diUb was purifed by applying the 2 mL reaction to a 26/60 Superdex 75 gel filtration column in PBS buffer at
pH 7.4.
Stably conjugated UbcH5B C85K S22R–Ub was generated as described previously (Dou et al., 2013): in brief, purified Arabidopsis
Uba1, UbcH5BC85K S22R and His-GST-Ubweremixed in 50mMTris-HCl, pH 9.0, 200mMNaCl, 10mMMgCl2 and 10mMATP for
1 day at 30C; the mixture was applied to a Ni2+-agarose column, cleaved with TEV, and further purified by cation exchange (Source
15S) followed by gel filtration chromatography (Superdex 75).
Absorbanceat 280 nmwasmeasured todetermine the concentrationsofUbvariants (including theUbVs) andUbV.pCBL-pCBL47–435
complex based on molar extinction coefficients calculated from the relevant sequences using Expasy’s ProtParam (Gasteiger et al.,
2005). Two concentrations were calculated for UbV.XRD based on treating it as a dimer or a monomer. Other protein concentrations
were determined by Bradford assay using BSA as a standard.
SPR Binding Assays
All SPR experiments were performed at 25C on a Biacore T200with a CM-5 chip (GEHealthcare). Anti-GSTwas coupled onto a CM-5
chipandGST-taggedE3swere captured to a level of 1,000–2,000 responseunits (Dou et al., 2012a).UbVsandUbcH5BS22RC85K–Ub
were serially diluted in running buffer containing 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1 mg/ml BSA, 1 mM DTT and 0.005% (v/v)
Tween-20. For experiments performed in the presence of UbVs and UbcH5B S22R C85K–Ub, UbcH5B S22R C85K–Ub was serially
diluted in running buffer containing 10 mM of the indicated UbV.XR variant in Table 1 and Figure S1. Binding was measured at the
concentration ranges indicated in Figure S1. Data reported are the difference in signal between GST-E3 variants and GST alone.
Solution NMR Experiments
All NMR experiments were carried out in 25mM sodium phosphate, 100mM NaCl, 5% (v/v) D2O buffer on a Bruker Avance III 600MHz
spectrometer equippedwith a cryogenic probe at 298K. 15N-HSQCspectrawere acquiredwith 8 scans over 128 points in the F2 dimen-
sion,with a spectrawidthof 18ppm.NMRdatawasprocessedusing TopSpin v3.1 andanalyzed inUCSFSparky. Assignment for human
E4Bwas taken fromBMRB-16623andconfirmedwith2DTOCSY.Chemical shift perturbations (CSPs)werecalculated from (Equation1):
CSP=
h
ðdHA­dHBÞ2 + ððdNA  dNBÞ=5Þ2
i1=2
Equation 1
Where the dH and dN are the proton and nitrogen chemical shifts, respectively for a given residue.
Analytical Gel Filtration
UbV.XR and variants were applied onto a Superdex 75 10/300 column (GE Healthcare) pre-equilibrated in 25 mM TrisHCl, pH 7.6,
150 mM NaCl, 1 mM DTT at constant flow-rate.
Crystallization
UbV.pCBL- pCBL47–435 Complex
A 3-fold molar excess of ZAP70 peptide (Dou et al., 2012a) was added to UbV.pCBL- pCBL47–435 complex (10 mg/ml) for crystalli-
zation. Crystals were obtained by sitting drop vapor diffusion from theMorpheus screen condition 62 (0.1Mmonosaccharides, 0.1 M
Buffer 1 pH 6.5, 50% Precipitant 2) using a 1:1 ratio of protein:reservoir. No further cryoprotection was required.
E4B1097–C
E4B1097–C (1000 mM) and UbV.E4B (1000 mM) were mixed in a 1:1 molar ratio and dialyzed against 150 mM NaCl, 25 mM Tris-HCl,
pH 7.6. Crystals of E4B1097–C alone were obtained from this mixture by hanging drop vapor diffusion using a 1:1 ratio of
protein:reservoir in Bis-Tris pH 5.5, 1.9 M ammonium sulfate and cryoprotected in mother liquor with an additional 20% glycerol.
XR-UbV.XR Complex
XR (1000 mM) and UbV.XR (1000 mM) were mixed in a 1:1.2 molar ratio. Crystals were obtained by sitting drop vapor diffusion in the
Classics Suite condition 44 (0.1 M NaHEPES pH 7.5, 1.4 M tri-Na citrate) using a 2:1 ratio of protein:reservoir and cryoprotected in
mother liquor with an additional 20% ethylene glycol. Crystals of UbV.XRD (600 mM) were obtained by sitting drop vapor diffusion in
JCSG+ condition 30 (0.2 M Zinc acetate, 0.1 M phosphate-citrate pH 4.2, 40% PEG 300) and swiftly pulled through 100% paraffin oil
before snap-freezing in liquid N2.
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Data Collection and Structure Determination
Data were collected at Diamond Light Source beamlines I03 and I04, and processed using the xia2 pipeline (Winter, 2010), including
XDS (Kabsch, 2010), POINTLESS (Evans, 2006), AIMLESS (Evans and Murshudov, 2013), and autoPROC (Vonrhein et al., 2011).
Models of XR generated by modifying BIRC3 RING (3EB5; Mace et al., 2008), pCBL47–435 (4A4C; Dou et al., 2012a), or UBE4B
U-box (3L1Z; Benirschke et al., 2010) andUb (from4V3K;Buetow et al., 2015), were used as initial searchmodels for PHASER (McCoy
et al., 2007). The structures were refined in BUSTER (Bricogne et al., 2016) or PHENIX (Adams et al., 2010), andmanually inspected in
COOT (Emsley et al., 2010). TLS parameterisation was used throughout. The final models were validated using MOLPROBITY
(Chen et al., 2010). All data processing and refinement statistics are presented in Table 2. Superimpositions and protein surface areas
were respectively calculated in LSQMAN (Kleywegt, 1996) and PISA (Krissinel and Henrick, 2007), and figures were made in PyMOL.
Autoubiquitination Assays
Autoubiquitination assays were performed at 23C in 50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 5 mM MgCl2, 5 mM ATP, 1 mM DTT,
0.3 U/ml inorganic pyrophosphatase, 0.3 U/ml creatine kinase and 5 mM creatine phosphate, Arabidopsis Uba1 (0.5 mM), UbcH5B
(5 mM), and 32P-Ub (100 mM) with the following: GST-pCBLR (0.75 mM) and UbV.pCBL (15 mM) or Ub74 (15 mM), GST-E4B (5 mM) and
UbV.E4B (100 mM) or Ub74 (100 mM), or GST-XR (2.5 mM) andUbV.XR (50 mM) or Ub74 (50 mM)where the final reaction concentrations
are given in parenthesis. Reactions were quenched at indicated time points with 2X loading dye containing 500mMDTT and resolved
by SDS-PAGE. Gels were dried and visualized by autoradiography.
Single-Turnover Lysine Discharge Assays
UbcH5B S22R (10 mM) was charged with Arabidopsis Uba1 (0.4 mM) and 32P-Ub (11.2 mM) for 15 min at 23C in 50 mM Tris-HCl
(pH 7.6), 50mMNaCl, 5 mMMgCl2, 5mMATP, 1mMDTT, BSA (1 mg/ml). For Figures 4B–4D, UbV.XRD and UbV.XRMwere included
in the charge. Charging was stopped by incubating the reaction with 0.01 U/ml apyrase and 30mM EDTA for 1-2 min. Discharge was
initiated by the addition of amixture containing 50mMTris-HCl (pH 7.6), 50mMNaCl, BSA (1mg/ml), L-lysine (150mM), E3 andUb74
or UbV. Concentrations of E3 and Ub74 or UbV were as follows: for Figure 2A, E4B (1 mM), UbV.E4B and Ub74 as indicated; for Fig-
ures 3A and 3G, pCBLR (60 nM), CBLR (1 mM), pCBL-B (75 nM), pCBL-C (42 nM), UbV.pCBL (10 mM) and Ub74 (10 mM); for Figure 3F,
pCBLR (60 nM), UbV.pCBL variants (2 mM) and Ub74 (2 mM); for Figure 4B, XR (350 nM), UbV.XRD (5 mMusing dimer molar extinction
coefficient or 10 mMusingmonomermolar extinction coefficient), UbV.XRM (10 mM) and Ub74 (10 mM); for Figure 4C, XR (200 nM) and
UbV.XRD and UbV.XRM as indicated; for Figure 4D, XR (200 nM) and UbV.XRD and UbV.XRM were at 1.11 mM based on the molar
extinction coefficient of a monomer and discharge at 1.5 min quantified; for Figure 4E, XR variants (350 nM), B2R (75 nM), UbV.XRD
(5 mM), and Ub74 (10 mM); for Figure 5C, XR (350 nM), UbV.XR variants (10 mM for monomers or 5 mM for dimers), and Ub74 (10 mM);
for Figure 5D, XR (350 nM), UbV.XR variants (10 mM for monomers or 5 mM for dimers), and Ub74 (10 mM); for Figure 5H, XR (350 nM),
UbV.XRD (5 mM), and Ub74 (10 mM). Reactions were quenched at indicated times with 4X loading dye and resolved by SDS-PAGE.
Gels were dried and visualized by autoradiography. For Figure 5H, Ub or Ub Q31R (11.2 mM) were used instead of 32P-Ub and
reactions were visualized by staining with InstantBlue (Expedeon). Final concentrations are in parenthesis except for UbcH5B
S22R and 32P-Ub, Ub or Ub Q31R, which were 5 mM and 5.6 mM, respectively. For assays in which effects or activities of several
mutants were compared (e.g., UbV.pCBL, UbV.pCBL Y66T Y68H and UbV.pCBL Q8L P11K or XR, XR T489E and XR F490R),
concentrations were normalized to unmutated variant or wild-type protein based on measured intensities of Coomassie stained
protein bands following separation by SDS-PAGE.
Single-Turnover Ub Transfer Reactions
UbcH5B S22R (5 mM) was charged with 32P-Ub (5.6 mM) and stopped as described for lysine discharge reactions but without BSA.
Ub transfer was initiated by the addition of: pCBL47–435 (1 mM) and UbV.pCBL (10 mM) or Ub74 (10 mM); GST-E4B (5 mM) and UbV.E4B
or Ub74 at indicated concentrations; XIAP (2 mM) and UbV.XRD (5 mM using dimer molar extinction coefficient or 10 mM using
monomer molar extinction coefficient) or Ub74 (10 mM); XIAP (2 mM), mSMAC (20 mM) and UbV.XRD (5 mM using dimer molar extinc-
tion coefficient or 10 mM using monomer molar extinction coefficient) or Ub74 (10 mM). Reactions were quenched at indicated times
with 4X loading dye, resolved by SDS-PAGE, dried and visualized by autoradiography. Final reaction concentrations are in
parenthesis.
Chemicals and Antibodies for Cell Culture
The chemicals used include hEGF, etoposide andMG132. Etoposide andMG132 were dissolved in DMSO and used at final concen-
trations of 75 mM and 50 mM, respectively. Where indicated, transfected cells were treated with etoposide for 18 hr and with MG132
for 4 hr prior to harvesting. Human EGF (hEGF) was dissolved in sterile PBS and used at a final concentration of 100 ng/ml for 10 min
unless otherwise stated in the figures. Before EGF treatment, the cells were serum starved for 24 hr. The following primary antibodies
were used: rabbit anti-FLAG, mouse anti-HA, mouse anti-Myc tag, mouse anti-GFP, mouse anti-Smac, mouse anti-EEA1, rabbit
anti-EGFR, rabbit anti-phospho-Akt, mouse anti-Akt, rabbit anti-phospho-Erk1/2, mouse Erk1/2, rabbit anti-ubiquitin, goat anti-Actin
and mounting medium with DAPI antibody. The secondary antibodies were donkey anti-goat IRDye 800CW, goat anti-rabbit IRDye
800CW, and goat anti-mouse IRDye 800CW, goat anti-rabbit Alexa Fluor 488, goat anti-mouse Alexa Fluor 594.
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Co-immunoprecipitation and Immunoblotting
The whole cell lysates (WCL) for western blotting were prepared in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL
CA-630, 10%glycerol 1.0mMDTT and cOmplete protease inhibitor cocktail as described previously (Ahmed et al., 2015). Lysates for
immunoprecipitation (IP) were prepared in 50mMNaHEPES, pH 7.2, 150mMNaCl, 10% glycerol, 1% IGEPAL CA-630, 1 mMEDTA,
0.5 mM DTT, 10 mM PMSF and cOmplete protease inhibitor cocktail using the same procedure. For immunoprecipitation, 1 mg of
freshly prepared whole cell lysates were incubated with 25 mL (50% slurry) 3:1 mixture of Protein A Sepharose CL 4B and Protein
G Sepharose 4 Fast Flow beads for pre-clearing at 4C for 30 min on a rotatory shaker. The supernatants were then collected
and incubatedwith the indicated antibodies at 4Covernight on a rotatory shaker. The next day, 35 mL (50%slurry) beadswere added
to the samples and incubated for 2 hr at 4C. The beads were microfuged at 2400 rpm for 2 min and washed once with IP lysis buffer
and twice with IP wash buffer (same as IP lysis buffer except for 200mMNaCl and 1.0 mMDTT). Beads were incubated with 40 mL 2X
loading dye at 95C for 10 min to elute the immunoprecipitated proteins. For immunoblotting fromwhole cell lysates, 50 mg of protein
were loaded per lane. Proteins were separated using SDS-PAGE under reducing conditions and transferred onto nitrocellulose
membrane (GE Healthcare Life Sciences). Blots were blocked with 5% BSA, washed with TBST and incubated with the respective
primary antibodies indicated in Figures 2, 3, and 4 at 4C overnight. The following day, the blots were visualized using an Odyssey
CLx Imaging System (LI-COR Biosciences) after incubation with the secondary antibodies.
Ubiquitination Assays in Cells
For cell-based ubiquitination assays, HEK293T cells were transfected with CMV-driven plasmids expressing His-Ub, FLAG-EGFR,
HA-UbV.pCBL, HA-UbV.XR and HA-Ub74 as indicated in Figures 3 and 4. Cells were harvested 48 hours post- transfection following
the addition of EGF, etoposide and MG132 as indicated. The WCLs were prepared with IP lysis buffer and 1 mg protein was incu-
bated with Ni-NTA resin for 4 hr at 4C. The beads were thenwashed once in IP lysis buffer, three times inWash buffer I (8MUrea, 1%
SDS in PBS) and once in wash buffer II (1% SDS in PBS). Pulled-down proteins were eluted in 40 mL 2X SDS sample loading buffer
following incubation at 95C for 10 min, separated using SDS-PAGE and probed for ubiquitinated adducts with immunoblotting.
Immunocytochemistry
The protocol described in Ahmed et al., 2015 was followed. Briefly, the cells were fixed with 4% paraformaldehyde, permeabilized
with 0.5% Triton X-100, and blocked with 3%BSA in PBS. This was followed by overnight incubation with primary antibodies at 4C,
then secondary antibodies for 1 h at room temperature under dark conditions. The images were captured with a DP71 camera
mounted on a BX51 fluorescencemicroscope (Olympus) using CellF software at 100X (oil) magnification. Post acquisition, the images
were processed to generate the merged (red, green and blue channels) figures with Fiji software.
cDNA Synthesis and Quantitative Real-Time PCR
TRIzol method was used to extract RNA from samples. RNA samples were checked for quality using A260/280 measurements and
agarose gel electrophoresis, cDNA were synthesized from the high quality RNA using the High capacity cDNA reverse transcription
kit (ThermoFisher Scientific). Quantitative PCR reaction mixtures contained of 400 ng cDNA and subsequently the reaction was
carried out in an Applied Biosystems 7500 Fast Real Time PCR system (ThermoFisher Scientific) using SYBR Green master mix
(ThermoFisher Scientific). In all the experiments, 18S rRNA was used as an internal control. Data collected from the instrument
were plotted in PRISM.
QUANTIFICIATION AND STATISTICAL ANALYSIS
For ELISAs and curves generated in Figure 1, EC50 values were calculated using the GraphPad Prism software with the built-in
equation formula (non-linear regression curve). For SPR assays, the data were analyzed by steady-state affinity analysis using
Biacore T200 BIAevaluation software (GE Healthcare) and Scrubber2 (BioLogic Software); data are presented as mean ± SEM in
Table 1 and the number of replicates (n) for each KD measurement is two (Figure S1). For Figure 4D, gels were exposed to a storage
phosphor screen (Fujifilm BAS-IP SR 2025) and the screen was read with a Typhoon FLA 7000 laser scanner (GE Healthcare). Image-
QuantTL 8.1 was used to quantify the intensity of each band (I) and the%UbcH5BUb remaining was calculated using the following
equation:
% UbcH5B  Ub remaining= 100  It= 1:5 min=It= 0 min
Data are presented as an average ± SD based on four replicates for each measurement.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the atomic coordinates of the structures determined in this work are as follows: PDB: 5O6T (XR-UbV.XR
complex), PDB: 5O6S (UbV.XR), PDB: 5O76 (ZAP70 peptide- CBL47–435-UbV.pCBL complex) and PDB: 5O75 (E4B1097–C). Raw gel
images and 32P-film scans have been deposited to Mendeley Data (https://doi.org/10.17632/hxd3cyxzrc.1).
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